TOLERATING A DEGREE OF SUBRETINAL FLUID IN THE TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) WITH RANIBIZUMAB USING A TREAT AND EXTEND REGIMEN: 24 MONTH RESULTS FROM THE PHASE IV, RANDOMISED, SINGLE-MASKED, MULTI-CENTRE FLUID STUDY